Abstract
In patients with no chromosomal abnormalities (NC-AML) treated with chemotherapy, the detection of an FLT3-ITD and a mutation in NPM1 have helped in defining three risk categories, the worst corresponding to AML with an ITD and no NPM1 mutation.[1][1]-[3][2] Recent studies on autologous
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
